These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 20354132)
1. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. Sekeres MA; List AF; Cuthbertson D; Paquette R; Ganetzky R; Latham D; Paulic K; Afable M; Saba HI; Loughran TP; Maciejewski JP J Clin Oncol; 2010 May; 28(13):2253-8. PubMed ID: 20354132 [TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Sekeres MA; Tiu RV; Komrokji R; Lancet J; Advani AS; Afable M; Englehaupt R; Juersivich J; Cuthbertson D; Paleveda J; Tabarroki A; Visconte V; Makishima H; Jerez A; Paquette R; List AF; Maciejewski JP Blood; 2012 Dec; 120(25):4945-51. PubMed ID: 22915641 [TBL] [Abstract][Full Text] [Related]
3. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol. Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS; Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027 [TBL] [Abstract][Full Text] [Related]
4. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423 [TBL] [Abstract][Full Text] [Related]
5. Treatment of higher-risk myelodysplastic syndrome. Garcia-Manero G Semin Oncol; 2011 Oct; 38(5):673-81. PubMed ID: 21943674 [TBL] [Abstract][Full Text] [Related]
6. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. Sekeres MA; Othus M; List AF; Odenike O; Stone RM; Gore SD; Litzow MR; Buckstein R; Fang M; Roulston D; Bloomfield CD; Moseley A; Nazha A; Zhang Y; Velasco MR; Gaur R; Atallah E; Attar EC; Cook EK; Cull AH; Rauh MJ; Appelbaum FR; Erba HP J Clin Oncol; 2017 Aug; 35(24):2745-2753. PubMed ID: 28486043 [TBL] [Abstract][Full Text] [Related]
7. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199 [TBL] [Abstract][Full Text] [Related]
8. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749 [TBL] [Abstract][Full Text] [Related]
9. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne. Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469 [TBL] [Abstract][Full Text] [Related]
10. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940 [TBL] [Abstract][Full Text] [Related]
11. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Sekeres MA; O'Keefe C; List AF; Paulic K; Afable M; Englehaupt R; Maciejewski JP Am J Hematol; 2011 Jan; 86(1):102-3. PubMed ID: 21080340 [TBL] [Abstract][Full Text] [Related]
12. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252 [TBL] [Abstract][Full Text] [Related]
13. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Ball B; Zeidan A; Gore SD; Prebet T Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579 [TBL] [Abstract][Full Text] [Related]